Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry

ConclusionDespite being on treatment, patients with MPN in MERGE had substantial symptom burden, which did not change over the course of the study. A discordance between physician and patient perception of symptom assessment was seen in this study, indicating that in addition to spleen and hematological investigations, a more systematic assessment such as the use of MPNSAF TSS could help to better evaluate patients' symptoms and understand the disease and its treatment burden.DisclosuresTaher: Celgene Corp.: Research Funding; Ionis Pharmaceuticals: Consultancy; Protagonist Therapeutics: Consultancy; La Jolla Pharmaceutical: Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Yassin: Novartis: Research Funding. Rippin: Employee of IQVIA - doing consultancy for Novartis: Consultancy. Sadek: Novartis Pharmaceutical Corporation: Employment. Siddiqui: Novartis Pharma AG: Employment, Equity Ownership. Wong: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.

Source: Blood - November 21, 2018 Category: Hematology Authors: Taher, A., Yassin, M. A., Xiao, Z., Hou, H.-A., Tuglular, T., Mathews, V., Rippin, G., Sadek, I., Siddiqui, A., Wong, R. S. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster III Source Type: research